A $100m investment by Bayer demonstrates the company’s continual commitment to science and innovation in the life sciences. Bayer HealthCare centers its research, development, and biotech manufacturing for the U.S. in the Bay Area. The new facility will permit the company to put their newly developed products to the test using the rigorous global regulatory requirements.
In a public announcement on April 14, the head of Global Development for Bayer’s Specialty Medicine Division said the company relishes the opportunity to strengthen their commitment to the patient community of hemophilia A sufferers. Bayer has worked on hemophilia treatment for over 25 years.
The Site Head at Bayer Berkeley and Senior Vice-President for Product Supply Biotech, Joerg Heidrich, was quoted as saying:
"Building upon our legacy in hemophilia A, we are delighted to continue Bayer's leadership in working to bring treatment options to patients around the world. As the Bay Area's third largest biotech employer, we are also proud to be making this contribution to the world's richest center of biotech R&D, investment, and production."
Literature ordered from a local Print company will likely detail the progress of the company’s efforts to the required government agencies, as well as healthcare providers. Get a Free Quote for Print